Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Original HTML
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
CONTACT:
Brendan Strong
Senior Vice President, Investor Relations
617.762.2661
[email protected]
SOURCE Karyopharm Therapeutics Inc.
Share this article
Original Summary
<p>NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was...</p>
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Karyopharm Grants 333 RSUs Under Nasdaq Inducement Rule", "body_html": "<p><strong>Newton, Mass. -- [CURRENT_DATE] --</strong> Karyopharm Therapeutics Inc. (Nasdaq: KPTI) granted 333 restricted stock units to one newly-hired employee as of September 30, 2026, under the company's 2022 Inducement Stock Incentive Plan.</p><h5>Grant complies with Nasdaq inducement rule for new hires</h5><p>The RSU award was issued as an inducement material to the employee's decision to join Karyopharm, in accordance with Nasdaq Listing Rule 5635(c)(4). The rule permits companies to issue equity awards outside shareholder-approved plans specifically to attract new personnel.</p><h5>Award vests over three years tied to continued service</h5><p>The 333 RSUs will vest in three equal installments of 33 1/3% on each of the first three anniversaries of the September 30, 2026 grant date. Vesting remains contingent on the employee's continued service to Karyopharm, whether as an employee or other service provider, through each applicable vesting date.</p><p>Karyopharm markets XPOVIO (selinexor), a first-in-class XPO1 inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and in more than 50 ex-U.S. markets under XPOVIO or NEXPOVIO branding.</p>", "meta_description": "Karyopharm Therapeutics granted 333 restricted stock units to a new hire under Nasdaq's inducement rule, vesting over three years.", "seo_keywords": "Karyopharm Therapeutics, KPTI, restricted stock units, Nasdaq inducement grant, XPOVIO, selinexor, equity compensation", "companies": ["Karyopharm Therapeutics Inc."], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["regulatory_update", "financial_disclosure"], "themes": ["corporate_governance", "compensation"], "products": ["XPOVIO"], "events": [], "cta_text": "Details on Karyopharm's equity inducement grant and compliance filing", "learn_more": "https://www.karyopharm.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
4de0040a6a7cfd41b8c5ecf08baa2a13
